Detail akcie ADMA Biologics online

Business Summary: ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Financial Summary: BRIEF: For the three months ended 31 March 2018, ADMA Biologics Inc revenues increased 54% to $4M. Net loss increased from $6.5M to $17.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Plasma Collection Center segment loss increase from $503K to $1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.39.